ATRS News and Press, Antares Pharma Inc. From 12/15/21

EWING, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced the divestiture of OTREXUP ® (methotrexate) injection for the treatment of rheumatoid arthritis to a subsidiary of A...

EWING, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at ...

Lipocine has obtained positive results in a phase 2 study using its drug LPCN1144 for the treatment of patients with NASH. TLANDO is being resubmitted to the FDA as a Class 1 resubmission with 2 months review time; possible FDA approval expected on January 28, 2022. It is estimate...

EWING, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at ...

The following slide deck was published by Antares Pharma, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Antares Pharma, Inc. 2021 Q3 - Results - Earnings Call Presentation

Antares Pharma, Inc. (ATRS) Q3 2021 Earnings Conference Call November 04, 2021, 08:30 AM ET Company Participants Tram Bui - VP-Corporate Communications and IR Bob Apple - President and CEO Joe Renda - SVP-Commercial Peter Richardson - EVP -Research and Development and Chief Medical Officer Fr...

ABC, ABUS, ACIW, ADAP, AES, AHCO, AKBA, ALBO, ALE, APD, APTV, ARW, ASPS, ATNX, ATRA, ATRS, BCE, BDX, BLDR, BLI, BLL, BRG, BXRX, CARS, CCOI, CFX, CHH, CI, CLDT, CMRX, CNHI, CNP, CNQ, COMM, CPE, CS, CTXS, CWEN, CYBR, DBRG, DEN, DIN, DISH, DLX, DNB, DOCN, DUK, EPAM, ERJ, ESTE, EURN, EVA, FIS, FW...

Antares Pharma (NASDAQ:ATRS) is scheduled to announce Q3 earnings results on Thursday, November 4th, before market open. The consensus EPS Estimate is $0.03 and the consensus Revenue Estimate is $47.93M (+19.8% Y/Y). The company reported second-quarter revenue and profit that beat Wall Street...

EWING, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced the appointment of Carmen Volkart to its Board of Directors. Ms. Volkart will also serve as a Member of the Audit Committee. ...

EWING, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that an abstract on XYOSTED ® , a subcutaneous testosterone enanthate injection, was accepted as on oral presentatio...